Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
51 hedge funds and large institutions have $119M invested in Carisma Therapeutics in 2015 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 2 closing their positions.
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
40% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 10
24% more funds holding
Funds holding: 41 → 51 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less capital invested
Capital invested by funds: $151M → $119M (-$32.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$4.25M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
+$2.29M |
| 3 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$1.91M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$1.31M |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$4.53M |
| 2 |
JP Morgan Chase
New York
|
-$728K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$181K |
| 4 |
TG
TCW Group
Los Angeles,
California
|
-$36K |
| 5 |
SO
STRS Ohio
Columbus,
Ohio
|
-$18.6K |
CARM Hedge Fund Activity: Q1 2015 in Review
51 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2015, worth a combined $119M — down 21% from $151M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CARM positions and 2 closed out — a net gain of 10 holders — while 14 added to existing stakes and 10 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $4.25M. The largest seller was Tekla Capital Management, cutting an estimated $4.53M.
- 51 institutional investors held Carisma Therapeutics (CARM) as of Q1 2015, up from 41 in Q4 2014.
- Funds reported $119M of Carisma Therapeutics stock for Q1 2015, down 21% quarter-over-quarter.
- 12 funds opened new Carisma Therapeutics positions in Q1 2015 and 2 closed out, a net change of +10 holders.
- The largest Carisma Therapeutics buyer in Q1 2015 was Royce & Associates, an estimated $4.25M added.
- The largest Carisma Therapeutics seller in Q1 2015 was Tekla Capital Management, an estimated $4.53M sold.
Based on aggregated 13F filings for Q1 2015.